Company Profile
ADMA Biologics Stock Price, News & Analysis
- Ticker:
- ADMA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
10.06 USD (+8.64%)
Close
Last updated: August 6, 2026
1.76B USD
Market cap
Why the stock is moving
Following the latest company update, “ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update”, ADMA closed up 8.64% at $10.06 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Plasma-Derived Biologics
ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection.
ASCENIV
ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for patients with primary humoral immunodeficiency, including complex later-line cases.
BIVIGAM and Manufacturing
BIVIGAM is a standard intravenous immunoglobulin product. ADMA controls plasma collection, fractionation, manufacturing and commercialization, allowing the company to manage supply and product mix internally.
SG-001
SG-001 is a pneumococcal hyperimmune-globulin development program intended to use ADMA's existing plasma, manufacturing and commercial infrastructure for an infectious-disease product.
Future catalysts
ADMA Biologics's catalysts are ASCENIV, BIVIGAM, and plasma-product manufacturing execution, with the stock mostly following commercial scale and supply discipline. The company moves on reliable commercialization more than on binary news.
Recent news
- 01
- 02
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
Source: ADMA Biologics
- 03
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
Source: ADMA Biologics
- 04
- 05
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
Source: ADMA Biologics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ADMA Biologics (ADMA)?
ADMA Biologics (ADMA) most recently closed at 10.06 USD, a +8.64% move versus the previous session.
What is the market cap of ADMA Biologics (ADMA)?
ADMA Biologics currently has a market capitalization of 1.76B USD on BioPharmSignal.
What does ADMA Biologics do?
Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for patients with primary...
On which exchange is ADMA stock listed?
ADMA Biologics (ADMA) is associated with NASDAQ, United States, Biopharma.
What is SG-001?
SG-001 SG-001 is a pneumococcal hyperimmune-globulin development program intended to use ADMA's existing plasma, manufacturing and commercial infrastructure for an infectious-disease product.
Which conditions is ADMA Biologics targeting with SG-001?
ADMA Biologics is associated with respiratory disease based on its company overview and current catalyst commentary.
How does ADMA Biologics describe recent progress with SG-001?
ADMA Biologics's catalysts are ASCENIV, BIVIGAM, and plasma-product manufacturing execution, with the stock mostly following commercial scale and supply discipline. The company moves on reliable commercialization more than on binary news.
What is Plasma-Derived?
Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S.